List view / Grid view
Understanding the cancer cell phenotype is central to both cancer diagnosis and treatment. Discrete molecular signatures among cancer phenotypes underpin patient stratification, while rapid methods for detailed phenotyping in the clinic (via liquid biopsies and tumour imaging) enable the delivery of personalised, effective precision medicines to the cancer patient...
Issue 4 of Drug Target Review looks at artificial intelligence in drug discovery and features In-Depth Focuses on Screening, Hit to Lead and Informatics.
When important and valuable patents expire, some rejoice and some dismay. Usually, after 20 years of protection, a masterpiece becomes available to all to reproduce, at the loss of the former patent owner...
Flow cytometry continues to evolve at a fast pace and provides neuroscientists with the ability to perform many highly-specialised assays simultaneously. It meets the demands of cutting-edge research in neuroscience that has allowed researchers to isolate particular neural cells from heterogeneous population and catalogue its molecular or physical features...
Image-based high-content screening (HCS) is a high-throughput screening (HTS) technology that combines automated fluorescence microscopy from microtiter plates with digital image analysis. This effectively allows phenotypic screening with sufficient throughput to interrogate large compound libraries...
Drugs exert therapeutically meaningful effects if they bind with appropriate selectively and potency to their respective targets. Although many of the assay techniques employed in early-stage drug discovery provide evidence that a drug is acting upon the target under investigation, this is often indirect and the site of action and…
Physiologically relevant models to evaluate the effects of drug candidates early in the drug discovery and development process are becoming increasingly important to develop. Various 3D cell/tissue models have emerged offering relevant environment for ex vivo assays, but significant progress is required to streamline and automate the end-to-end workflow. Several…
The ever-increasing pressure to turn bench-top discoveries into new therapies has led to the re-purposing of embryonic stem cell lines, originally intended for basic research, for clinical applications...
Flow cytometry has become a widely used technology in life science research. It is also essential for many pharma and biotechnology companies due to its proficiency in identifying biomarkers, developing biopharmaceuticals, and assessing the efficiency of new pharmacological protocols...
The multiplex and high-throughput capabilities of next-generation sequencing (NGS) allow researchers to study an immense number of DNA/RNA molecules per run, bringing opportunities to study biological or clinical research questions that could not be addressed before...
The Wellcome Trust Sanger Institute's Kim Judge explains how Next Generation Sequencing forms a crucial part of the scientist’s toolkit and makes a valuable contribution to the field of drug discovery...
Pushpanathan Muthuirulan & Pooja Sharma explain how high-throughput next-generation sequencing (NGS) technologies are revolutionising our ability to characterise infectious diseases at genomic, transcriptomic and epigenetic levels...
Next-generation sequencing (NGS) has greatly increased our understanding of biological phenomena and human disease. In particular, single-cell sequencing is one of the fastest-growing applications...
Next-generation sequencing is a crucial part of the scientist's toolkit. This in-depth focus compares the strengths and weaknesses of a range of NGS technologies and examines the benefits and challenges of using it in infectious disease diagnosis...
Using next-generation sequencing techniques enables pharmaceutical companies to explore the molecular landscape of disease initiation and progression with unprecedented clarity. Dr Sam Rulli, Product Manager at QIAGEN, provides his insight into the major challenges researchers face...
